首页|玻璃体内注射抗VEGF药物治疗糖尿病性视网膜病变的不良反应研究进展

玻璃体内注射抗VEGF药物治疗糖尿病性视网膜病变的不良反应研究进展

Progress on adverse events study with intravitreal injection of anti-VEGF drugs used in the treatment of diabetic retinopathy

扫码查看
糖尿病性视网膜病变(DR)已经成为威胁糖尿病患者视力的主要因素.血管内皮生长因子(VEGF)的异常表达被认为是DR的核心发病机制.玻璃体内注射抗VEGF药物可以快速抑制新生血管的形成及降低血管通透性,能有效控制疾病的发展.抗VEGF药物已经广泛应用于DR的治疗,近年来玻璃体内注射抗VEGF药物次数呈爆发式增长.虽然玻璃体内注射抗VEGF药物是相对安全的治疗方式,但其所带来的不良反应仍时有发生.因此,本文将对玻璃体内注射抗VEGF药物治疗DR眼部及全身的不良反应展开综述.
Diabetic retinopathy(DR)has become a major threat to vision in diabetes.Abnormal expression of vascular endothelial growth factor(VEGF)is considered to be the core pathological mechanism of DR.Intravitreal injection of anti-VEGF drugs can quickly inhibit neovascularization and reduce vascular permeability,effectively controlling the progression of the disease.Anti-VEGF drugs have been widely used in the treatment for DR,and the number of intravitreal injections for anti-VEGF drugs has been increasing explosively in recent years.Although intravitreal injection of anti-VEGF drugs is a relatively safe treatment method,it can still cause adverse reactions.Therefore,this article will provide an overview of the adverse reactions of intravitreal injection of anti-VEGF drugs in the treatment for DR in both ocular and systemic aspects.

Injection,intravitrealDrugs,anti-VEGFRetinopathy,diabeticEvent,adverse,ocularSystemic adverse events

刘方圆、刘东成、刘子凌、秦波

展开 >

暨南大学第二临床医学院,深圳 518020

深圳爱尔眼科医院 暨南大学附属爱尔眼科医院,深圳 518032

深圳市爱尔眼科技术研究所,深圳 518032

注射,玻璃体内 药物,抗VEGF 视网膜病变,糖尿病性 反应,不良,眼部 反应,不良,全身

爱尔眼科医院集团科研基金爱尔眼科医院集团科研基金湖南省湘江公益基金会科研基金

AF2201D07AM2101D1

2023

中华眼外伤职业眼病杂志
中华医学会

中华眼外伤职业眼病杂志

影响因子:0.622
ISSN:2095-1477
年,卷(期):2023.45(11)
  • 50